Comparison of the effect of vaginal progesterone on uterine Doppler findings in early-onset preeclampsia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210127050156N1

Enrollment

Registered

2021-03-03

Start date

2021-03-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia. Pre-eclampsia

Interventions

Intervention 1: Intervention group: Progesterone vaginal suppository 200 mg (Aburaihan pharmaceutical company) every night for one week. Intervention 2: Control group: Without intervention.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: gestational age between 24-32 weeks Increased uterine artery resistance Single pregnancy Patients with a history of lupus antiphospholipid syndrome History of high blood pressure Previous history of preeclampsia Diabetic

Exclusion criteria

Exclusion criteria: Having kidney, liver and heart disease Having progesterone sensitivity Having severe preeclampsia Rupture of membrance Patients with cardiomyopathy; Evidence of fetal growth retardation; Ultrasound evidence of life-threatening congenital anomalies Use assisted reproductive techniques such as IVF

Design outcomes

Primary

Measure	Time frame
Uterine artery resistance. Timepoint: Before and one week after the intervention. Method of measurement: Doppler ultrasound.;Symptoms of preeclampsia. Timepoint: During pregnancy. Method of measurement: Doctor's opinion.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoomeh Farahani

Karaj University of Medical Sciences

m.farahanii@abzums.ac.ir+98 26 3222 2021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026